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The incidence of acute leukemia is increasing worldwide.1-3 As the population ages, it is an-ticipated that an even greater number of patients 
will be diagnosed with this malignancy.4,5 The overall inci-
dence of acute lymphoblastic leukemia (ALL) is 1 to 1.5 
per 100 000 persons,6 with a bimodal distribution at ages 
4 to 5 years (with an incidence as high as 4 to 5 per 100 000 
persons) and at age 50 years (with an incidence 2 per 
100 000 persons).6 There are no reports clearly describing 
the incidence of ALL in developing countries. The most 
important studies about outcome of acute leukemias 
come from developed countries, whereas most of the 
patients with this disease are in developing countries 
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BACKGROUND AND OBJECTIVES: the most important studies about outcome of acute leukemia come from 
developed countries, whereas most of the patients with this disease are in developing countries. We report pre-
dictive and prognostic factors in patients with acute lymphoblastic leukemia (all) in a tertiary care center in a 
developing country. 
PATIENTS AND METHODS: We retrospectively reviewed the records of adult patients with acute leukemia who 
were referred to the american university of beirut medical center between 1996 and early 2006. 
RESULTS: of 105 patients, 36 (34%) patients were diagnosed with all, and included 19 (53%) males and 17 
(47%) females with a median age of 34 years (range, 14-79 years). induction chemotherapy with curative intent 
was administered to 34 (94%) patients. twenty-seven patients received intrathecal chemotherapy as prophylaxis 
(n=24) or as treatment for cns disease (n=3). twenty-eight patients (82%) achieved complete remission (cr) 
after induction chemotherapy. the median overall survival (os) time was 22 months and the five-year os for 
all patients was 38%. the median disease-free survival (dfs) time was 12 months, while the five-year dfs was 
38%. multivariate analysis showed that age <40 years, Wbc <30×109/l, achievement of cr after first induction, 
and cns prophylaxis were predictive factors for os and dfs. 
CONCLUSION: despite limitations and the relatively low socioeconomic status of the lebanese population, 
os (38%) and dfs (38%) are quite similar to international data. trends toward a higher cr and dfs in adults 
are due to intensified consolidation chemotherapy, the use of stem cell transplantation, and improvements in 
supportive care.
based on the distribution of the would be world’s popu-
lation.7,8 In ALL, the most important prognostic factor 
for overall survival is age,9 while the most important fac-
tor for disease-free survival (DFS) is karyotype.10 The 
5-year overall survival (OS) of adult patients with ALL 
is 20% to 40%.11-15 For those less than 30 years of age, 
the OS is 34% to 57%, compared to 15% to 17% for 
patients older than 50 years of age.16-20
Moreover, although most cases of ALL are found in 
developing countries, there is scarcity of data in the lit-
erature reflecting the condition of these patients includ-
ing clinical features, description of prognostic factors and 
predictors as well as the outcome. In this manuscript, we 
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report predictive and prognostic factors in patients with 
ALL in a tertiary care center in a developing country.
PATIENTS AND METHODS 
We retrospectively reviewed the records of consecu-
tive patients with newly diagnosed and previously un-
treated acute leukemia who were referred to the adult 
hematology service of the American University of 
Beirut Medical Center (AUB-MC) between 1996 and 
early 2006. The number of patients reviewed was 131. 
These patients were studied for family and personal 
history, medical history, disease presentation, and 
management and outcome of leukemia. The biological 
characteristics of the leukemia including morphologi-
cal, immunophenotypic, cytogenetic and molecular 
data were also analyzed.
A morphological review of all cases was performed by 
one hematopathologist (RM). Twenty-six patients were 
excluded from this study; 14 of these were diagnosed but 
not treated at AUB-MC, 6 patients were rediagnosed as 
having hematologic malignancies other than acute leu-
kemia, and the remaining 6 patients did not have suf-
ficient data to be included in the analysis. Therefore, a 
total of 105 patients were included in the data collected. 
Of these 105 patients, 69 (66%) had acute myelogenous 
leukemia (AML) and 36 patients (34%) had ALL. This 
study was approved by the Institutional Review Board 
at AUB-Faculty of Medicine. Hospital records of the 
patients were reviewed in the Department of Medical 
Records and the private clinics. Phone calls were also 
done for the most recent follow up of patients.
The diagnosis of ALL was made according to 
the French-American-British (FAB) morphologi-
cal and cytochemical criteria.21 Cytogenetic analysis 
was performed routinely using standard methods. 
Immunophenotyping was also performed using flow cy-
tometry. Bone marrow aspirate and/or biopsy were ana-
lyzed for cellularity and blast count. Blood chemistry, 
complete blood count (CBC), coagulation profile, and 
left ventricular ejection fraction data were collected. 
For assessment of response, bone marrow aspi-
rate was performed at the end of the induction phase. 
Complete hematological remission (CR) was defined 
as less than 5% marrow blasts with normal peripheral 
blood counts and differential, with no evidence of ex-
tramedullary leukemia. Partial remission (PR) required 
similar criteria except for the presence of 5% to 20% 
marrow blasts. Resistance was defined as persistent leu-
kemia in blood and/or bone marrow in patients surviv-
ing more than 1 month after start of induction treat-
ment. Death during induction was defined as death 
that occurred while the patient was receiving induction 
Table 1. Patient’s characteristics at presentation.
Patient characteristics Patients (n=36)
Male/female 19/17
Median age (range) (years) 34 (14-79)
Clinical findings
   Lymphadenopathy 8 (22%)
   Hepatomegaly 0 (0%)
   Splenomegaly 6 (17%)
   Testicular involvement 0 (0%)
   Mediastinal enlargement 0 (0%)
   Fever 16 (44%)
   Bleeding 0 (0%)
   Fatigue 21 (58%)
Laboratory findings   (normal range) Median  (range)
   LDH, iU/L 
   (normal range, 110-265 iU/L) 2023.9 (101-8948)
   wBC, ×109/L  
   (normal range, 4.0-11.0×109/L) 64.8 (1-484)
   Hemoglobin, g/dL  
   (Male: normal range, 13-18 g/dL)
   (Female: normal range, 12-16 g/dL)
9.5 (5.4-14.3)
   Blasts, %              40 (0-94)
   Platelets, ×109/L   
   (normal range, 150-400×109/L) 104 (8-368)
LDH: lactate dehydrogenase; wBC: white blood cell count
Death during 
induction
n=5 patients (15%)
induction failure
n=3 patients (9%)
Reinduction
Complete remission
n=2 patients
Death
n=1 patients
Total complete 
remission
n=28 patients (78%)
aLL
n=36 patients
Supportive treatment 
n=2 patients (6%)
induction chemo-
therapy 
n=34 patients (94%)
Complete remission
n=26 patients (76%)
Figure 1. Disposition of 36 patients with  acute lymphoblastic leukemia (aLL).
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Figure 2. Overall and disease-free survival for 36 patients with acute lymphoblastic 
leukemia.
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Figure 3a. Overall survival by age.
therapy. Disease-free survival (DFS) was defined as the 
time from the first day of CR to relapse, death, or last 
visit, and overall survival (OS) as the time from the day 
of diagnosis to death or last visit. Hematological relapse 
was considered when more than 5% blasts were seen 
in bone marrow aspirates as confirmed by flow cytom-
etry. We describe numerical variables by their median 
and range, whereas categorical variables are described 
by their relative frequencies and counts. Survival curves 
were calculated according to the methods of Kaplan and 
Meier and compared between groups with the log-rank 
test.22 Differences were considered statistically significant 
when the P value was less than .05. Potential prognostic 
factors tested for the univariate analysis comprised age, 
sex, WBC count, hemoglobin, platelet count, percentage 
of blasts in the bone marrow, cytogenetic abnormalities, 
CNS involvement, type of chemotherapy and response 
to first induction chemotherapy. Univariate and multi-
variate analysis were done for all factors assessed. The 
analyses were performed using SPSS software version 
15.0 (SPSS, Chicago, IL, USA).
RESULTS
Initial Presentation
Of the 105 patients analyzed, 36 (34%) patients were 
diagnosed with ALL (Table 1) and 69 (66%) patients 
were diagnosed with AML. There were 19 (53%) 
males and 17 (47%) females with a median age of 
34 years (range 14-79 years). Five patients were <18 
years and 2 patients were ≥60 years old at diagnosis. 
The symptoms at presentation of these patients were 
fatigue (58%), weakness (47%), fever (44%), pallor 
(31%), weight loss (28%) and anorexia (25%). Of the 
36 ALL patients, only 3 had CNS involvement at pre-
sentation. The patients had a median WBC count of 
64.8×109/L (1-48.4), a median hemoglobin count of 
9.5 g/dL (5.4-14.3), and a median platelet count of 
104×109/L (8-36.8). Seventeen patients (53%) had a 
blast count of < 30% on peripheral blood. Thirty-one 
patients (86.1%) had B-ALL and 5 patients (13.9%) 
had T-ALL. Twelve patients (33%) had abnormal 
karyotype including 5 patients with Philadelphia pos-
itive ALL, 17 patients (47%) had normal karyotype, 
and 7 patients (20%) had failed or missing karyotype 
testing result. 
Response to induction chemotherapy
Induction chemotherapy with curative intent was 
administered to 34 patients (94%), and the remain-
ing 2 patients (6%) received palliative chemotherapy 
due to old age, poor performance status, or severe 
concomitant diseases. Induction chemotherapy con-
sisted of BFM 90-like regimen (21 patients, 58%),23 
HyperCVAD protocol24 (7 patients, 20%) and various 
other regimens (6 patients, 17%). At the discretion of 
the attending physicians, 27 patients received intra-
thecal chemotherapy as prophylaxis (n=24) or treat-
ment of CNS disease (n=3). Of the 34 patients who 
received induction chemotherapy with curative intent, 
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Figure 4a. Overall survival by wBC count.
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Figure 3b. Disease-free survival by age.
ther consolidation and maintenance chemotherapy. 
Of the patients who achieved a first CR, 13 patients 
relapsed and were treated with chemotherapy. Four 
patients underwent stem cell transplantation. 
Survival and prognostic factors
The median follow-up of the patients was 18.5 months. 
The median OS time was 22 months and the 5-year 
OS of ALL patients was 38% (Figure 2). The median 
DFS was 12 months, while the 5-year DFS was 38%. 
Multivariate analysis showed that age <40 years, WBC 
<30×109/L, and achievement of CR after first induc-
tion were predictive factors for OS and DFS. Twenty-
three patients with age less than 40 years had a median 
OS of 56 months and a 5-year OS of 46% compared 
with 13 patients 40 years of age or older who had a me-
dian OS of 14 months (P=.013) (Figure 3a). Median 
DFS time was 19 months and 5-year DFS was 43% for 
patients less than 40 years old compared with 3 months 
for patients 40 years of age or older (P=.079) (Figure 
3b). No patient in the latter group had 5 years of DFS. 
Twenty-two patients with WBC <30×109/L had a me-
dian OS time of 42 months compared with 14 patients 
with WBC ≥30×109/L with median OS time of 11 
months (P=.024) (Figure 4a). There was no significant 
difference in DFS between these two groups, probably 
because of the small sample size (Figure 4b). Twenty-
six patients who achieved CR after first induction had 
a median OS of 56 months compared with 6 months 
for the 10 patients who did not achieve CR (P<.0001) 
(Figure 5). There was no significant difference in sur-
vival according to immunophenotype (B or T cell lin-
eage). Median OS for B lineage (n=31) and T lineage 
(n=5) cells were 44.2 and 59.2 months, respectively) 
(P=.287). Karyotype results were available for 29 pa-
tients at presentation. They were classified into three 
groups according to karyotype: the good karyotype 
group (n=14) included patients with normal karyo-
type, and patients with 9p deletions; the “standard-risk” 
karyotype group (n=6) included patients with del(6q), 
hyperdiploidy, and miscellaneous translocations; and 
the high-risk karyotype group (n=9) included t(9;22), 
t(4;11), and t(1;19).25 According to this classification, 
the difference in OS or DFS was not statistically signifi-
cant between the three groups (data not shown). The 
median OS time for good karyotype, “standard-risk” 
karyotype, and bad karyotype groups were 56, 16, and 
12 months, respectively (P=.182), and the median DFS 
for the good and bad karyotype groups were 24 and 17 
months, respectively, and the median DFS for “stan-
dard-risk” karyotype was not reached (P=.814). Three 
patients of 36 (8.3%) had initial CNS involvement. The 
26 (72%) patients achieved CR after first induction, 
5 (15%) patients died during induction and 3 (9%) 
patients had persistent blasts at day 21-28 (Figure 
1). These 3 patients received a second induction; two 
of them achieved CR and one died. The two patients 
who received palliative chemotherapy died of septic 
shock at day 43 and 171. Overall 28 patients achieved 
CR after induction chemotherapy and received fur-
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Figure 4b. Disease-free survival by wBC count.
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Figure 5. Overall survival by complete remission after first induction.
median OS time for patients receiving CNS prophylaxis 
(n=24) or treatment (n=3) with intrathecal methotrex-
ate was 42 months compared with 11 months for those 
who did not receive intrathecal prophylaxis or treatment 
(n=9) (P=.001) (Figure 6a), while the median DFS for 
patients receiving CNS prophylaxis or treatment with 
intrathecal methotrexate was 19 months compared to 
0 months in those who did not receive intrathecal pro-
phylaxis or treatment (P=.004) (Figure 6b). There was 
no significant difference in OS and DFS among differ-
ent treatment regimens (data not shown). 
DISCUSSION
This report describes the results of 36 ALL patients from a 
tertiary care center in a developing country. There is limit-
ed access of patients to such centers mainly due to financial 
reasons, since many third party payers do not cover centers 
such as AUB-MC. The average worldwide incidence of 
adult ALL is 1 per 100 000. Therefore, we expect to have 
40 patients diagnosed with adult ALL per year in country 
like Lebanon where the population is around 4 000 000. 
Since our center accommodates almost 10% of the patients 
in Lebanon, four patients with ALL are to be admitted to 
the center yearly. This explains the limited number of adult 
patients with ALL in our center. 
The prognosis of adults with ALL remains poor 
with a reported 5-year survival of 20% to 40%.14,26,27 
Overall, our patients had 5-year OS and DFS rates of 
38%, quite comparable to the results from developed 
countries. However, treatment-related mortality rate 
was 15% (5 patients out of 34), which is more than 
that reported in the literature (5-10%).28 As expected, 
patients who achieved CR after first induction showed 
a better OS than those who did not (median of 56 vs 6 
months, respectively) (P<.0001).
In our population of 36 consecutive ALL patients, 
the most common clinical symptoms at presentation 
were non-specific, consisting mainly of fatigue, weak-
ness, fever, pallor, weight loss and anorexia. This is in 
keeping with the classical presentations described in 
the medical literature.29-31 However, the median age (34 
years) was significantly lower than in developed coun-
tries (median, 37 years),19 reflecting both the younger 
age of the Lebanese population and a potential bias of 
referral to AUB-MC. Age has been described as a well 
known prognostic factor in ALL,32 and even as the most 
important prognostic factor for survival.33 In ALL, as 
age increases, OS continuously decreases.16-19 Different 
working groups defined different cut-off points for age 
as prognostic factors. Almost two-thirds of our patients 
were younger than 40 years of age and they had a better 
survival than patients older 40 years of age (56 versus 
16 months, P=.013). There was no significant differ-
ence in survival according to gender.
Previous reports consistently showed that high white 
blood count is associated with higher risk of relapse and 
poorer OS.16,19,20,34 This is mostly true with ALL of B-
cell origin.9 Most of our patients have ALL of B-cell 
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Figure 6b. Disease-free survival by intrathecal chemotherapy.
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Figure 6a. Overall survival by intrathecal chemotherapy.
origin and accordingly, in our group, patients with WBC 
<30×109/L had an OS of 42 months compared with 14 
months for those with a WBC >30×109/L (P=.024). 
However, there was no significant difference in survival 
among patients with different subtypes of ALL (B and T 
cell lineage). This could be due to the insufficient number 
of patients that are needed for such a comparison.
Traditionally cytogenetics are described as the most 
important prognostic factor for DFS10,35,36 with t (9,22) 
having the worst prognosis in adult ALL before the era 
of imatinib mesylate.13 However, our population did 
not show any significant difference in CR rate or sur-
vival according to cytogenetic risk groups. This could be 
due to the small number of patients we have compared 
with the huge diversity of cytogenetic abnormalities de-
scribed in the literature so far. 
Different induction chemotherapy protocols were 
used, mostly BFM-like or MD Anderson HyperCVAD 
regimen. Indeed, until June 2008, there were no unified 
treatment protocols for adult ALL patients at AUB-
MC. Different attending physicians used different 
regimen based on their previous experience, a situation 
frequently encountered in developing countries. An 
absence of a difference in OS when comparing differ-
ent treatment regimens is in accordance with the fact 
that in the literature, until now, there is no advantage of 
one regimen over the other in ALL. Nevertheless, our 
results confirmed that patients who received intathe-
cal chemotherapy had a better OS than those who did 
not (42 versus 11 months, P=.001). Recently, following 
the establishment of a sister institution status between 
AUB-MC and the MD Anderson Cancer Center, uni-
fied protocols have been established for the treatment 
of adult acute leukemia. Later on, outcomes of patients 
prospectively included in the unified protocols will be 
presented to show the potential benefit of unified pro-
tocols in a tertiary care center in a developing country. 
We have reported predictive and prognostic fac-
tors in patients with ALL in a tertiary care center in 
a developing country. Significant prognostic factors in 
our treated group were age, WBC count more than 
30×109/L, achievement of CR after the first induction, 
and CNS prophylaxis, while the type of chemotherapy 
regimen did not show any effect on survival. Factors de-
scribed earlier in the literature to affect survival such as 
cytogenetic abnormalities, and cell lineage were not sig-
nificant in our study, probably due to the relatively few 
patients. Despite all the above limitations and the rela-
tively low socioeconomic status of the Lebanese popula-
tion (Lebanon is still considered a developing country 
with a gross domestic product of 4500 US dollars per 
capita), the OS of our patients (38%) and DFS (38%) 
were quite similar to the international data.14,26,27
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